Restriction of PD-1 function by cis -PD-L1/CD80 interactions is required for optimal T cell responses
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Sparing T cells from inhibition Programmed cell death 1 (PD-1) is an inhibitory receptor that normally keeps T cell immune responses in check. Immunotherapy targeting PD-1 has proven successful for certain types of cancer, but it remains unclear how PD-1 is regulated. Sugiura et al. found that a costimulatory molecule, CD80, can restrict PD-1 function during the activation of T lymphocytes. Binding of CD80 to the PD-1 ligand PD-L1 in cis on primary activated dendritic cells interfered with the ability of PD-L1 to access PD-1 on T cells, which would otherwise have inhibited T cell activation. Functional insights into PD-L1–CD80 interactions may explain the outcomes of anti–PD-1 and anti–PD-L1 cancer therapy. Science , this issue p. 558
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, PD‐L1 can interact in cis with Cluster of differentiation 80 (CD80) to PD‐1 [276, 277, 278], which may disturb the PD‐L1 and PD‐1 interaction and the CTLA4 and CD80 interaction and also maintain the flexibility of CD80 to trigger the signaling of CD28 [277, 279].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [278]
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Cited by
Items 101–200 of 393
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
Battin, C., Leitner, J. M., Waidhofer‐Söllner, P., Grabmeier‐Pfistershammer, K., Olive, D., & Steinberger, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956694 · Cited by 47
Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment
Lucarini, V., Melaiu, O., Tempora, P., D’Amico, S., Locatelli, F., & Fruci, D. (2021) · Cancers · doi:10.3390/cancers13030433 · Cited by 50
Review of MXene-Derived Quantum Dots for Cancer Theranostics
Zhu, Y., Feng, L., Zhao, R., Liu, B., & Yang, P. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c05675 · Cited by 43
Frijlink, E., Bosma, D. M. T., Busselaar, J., Battaglia, T., Staal, M. D., Verbrugge, I., & Borst, J. G. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171154 · Cited by 46
Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy
Liu, C., Zhang, G., Xiang, K., Kim, Y., Lavoie, R. R., Lucien, F., & Wen, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03097-x · Cited by 42
Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N. (2021) · Advanced Biology · doi:10.1002/adbi.202100758 · Cited by 39
Iida, Y., Yoshikawa, R., Murata, A., Kotani, H., Kazuki, Y., Oshimura, M., Matsuzaki, Y., & Harada, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000582 · Cited by 41
Hu, H., Ding, Y., Gao, Z., & Li, H. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.129442 · Cited by 39
Lobo, C. S., Mendes, M. I. P., Pereira, D. A., Gomes-da-Silva, L. C., & Arnaut, L. G. (2023) · Scientific Reports · doi:10.1038/s41598-023-38862-8 · Cited by 45
Lymphatic system regulation of anti-cancer immunity and metastasis
Lei, P., Fraser, C. S., Jones, D., Ubellacker, J. M., & Padera, T. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1449291 · Cited by 45
Protein homodimer sequestration with small molecules: Focus on PD-L1
Bailly, C., & Vergoten, G. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113821 · Cited by 39
Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity
Zhang, Y., Song, Q., Cassady, K. M., Lee, M., Tang, H., Zheng, M., Wang, B., Schones, D. E., Fu, Y., Riggs, A. D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205085120 · Cited by 43
Kennedy, A., Robinson, M. A., Hinze, C., Waters, E., Williams, C., Halliday, N., Dovedi, S. J., & Sansom, D. M. (2023) · The EMBO Journal · doi:10.15252/embj.2022111556 · Cited by 39
Functional differences between rodent and human PD-1 linked to evolutionary divergence
Masubuchi, T., Chen, L., Marcel, N., Wen, G. A., Caron, C., Zhang, J., Zhao, Y., Morris, G. P., Chen, X., Hedrick, S. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads6295 · Cited by 36
Becker, M. W., Peters, L. D., Myint, T. S., Smurlick, D., Powell, A., Brusko, T. M., & Phelps, E. A. (2023) · Science Advances · doi:10.1126/sciadv.adg1082 · Cited by 37
Zhang, L., Yang, J., Chen, G., Xie, Q., Fu, Q.-Y., Xia, H.-F., Li, Y., Huang, J., Li, Y., Wu, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48200-9 · Cited by 36
Delyon, J., Zuber, J., Dorent, R., Poujol‐Robert, A., Péraldi, M., Anglicheau, D., & Lebbé, C. (2020) · Transplantation · doi:10.1097/tp.0000000000003292 · Cited by 35
Nakamura, K., Yagyu, S., Hirota, S., Tomida, A., Kondo, M., Shigeura, T., Hasegawa, A., Tanaka, M., & Nakazawa, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.011 · Cited by 39
Zhang, S., Feng, Y., Meng, M., Li, Z., Li, H., Lin, L., Xu, C., Chen, J., Hao, K., Tang, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121794 · Cited by 36
Martomo, S. A., Lü, D., Polonskaya, Z., Luna, X., Zhang, Z., Feldstein, S. F., Lumban-Tobing, R., Almstead, D. K., Miyara, F., & Patel, J. P. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0457 · Cited by 35
Ibañez-Vega, J., Vilchez, C., Jimenez, K., Carlos Guevara, O., Burgos, P. I., & Naves, R. F. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102702 · Cited by 35
Takehara, T., Wakamatsu, E., Machiyama, H., Nishi, W., Emoto, K., Azuma, M., Soejima, K., Fukunaga, K., & Yokosuka, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02111-3 · Cited by 31
Vitale, L. A., He, L.-Z., Thomas, L. J., Wasiuk, A., O’Neill, T. J., Widger, J., Crocker, A., Mills‐Chen, L., Forsberg, E. M., Weidlick, J., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02610-y · Cited by 36
Ando, H., Suzuki, K., & Yanagihara, T. (2021) · Biomedicines · doi:10.3390/biomedicines9101484 · Cited by 31
Kanda, Y., Okazaki, T., & Katakai, T. (2021) · Cancers · doi:10.3390/cancers13184616 · Cited by 36
Self-citationMechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex
Garrett-Thomson, S. C., Massimi, A. B., Fedorov, E. V., Bonanno, J. B., Scandiuzzi, L., Hillerich, B., Seidel, R. D., Love, J. D., Garforth, S., Guha, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233578 · Cited by 31
Garcia, M. G., Deng, Y., Murray, C. E., Reyes, R. M., Padron, A. S., Bai, H., Kancharla, A., Gupta, H. B., Shen-Orr, S. S., & Curiel, T. J. (2022) · Aging and Cancer · doi:10.1002/aac2.12045 · Cited by 30
zDHHC20-driven S-palmitoylation of CD80 is required for its costimulatory function
Lu, B., Sun, Y.-Y., Chen, B., Yang, B., He, Q., Li, J., & Cao, J. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01248-1 · Cited by 31
Aire suppresses CTLA-4 expression from the thymic stroma to control autoimmunity
Morimoto, J. O., Matsumoto, M., Miyazawa, R., Yoshida, H., Tsuneyama, K., & Matsumoto, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110384 · Cited by 29
Riemann, D., Schütte, W., Turzer, S., Seliger, B., & Möller, M. (2020) · Cancers · doi:10.3390/cancers12102966 · Cited by 28
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
Hu, L., Sun, C., Yuan, K., & Yang, P. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104181 · Cited by 30
Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response
Xiao, Z., Wang, J., Yang, J., Guo, F., Zhang, L., & Zhang, L. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100128 · Cited by 33
Sun, F., Li, L., Xiao, Y., Gregory, A. D., Shapiro, S. D., Xiao, G., & Qu, Z. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100046 · Cited by 29
PD-1 preferentially inhibits the activation of low-affinity T cells
Shimizu, K., Sugiura, D., Okazaki, I., Maruhashi, T., Takemoto, T., & Okazaki, T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107141118 · Cited by 30
Self-citationCardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs
Montisci, A., Vietri, M. T., Palmieri, V., Sala, S., Donatelli, F., & Napoli, C. (2021) · Cancers · doi:10.3390/cancers13194797 · Cited by 28
Checkpoint: Inspecting the barriers in glioblastoma immunotherapies
Preddy, I., Nandoliya, K. R., Miska, J. M., & Ahmed, A. U. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.012 · Cited by 29
In Vivo Imaging of Local Inflammation: Monitoring LPS-Induced CD80/CD86 Upregulation by PET
Taddio, M. F., Jaramillo, C. A. C., Runge, P., Blanc, A., Keller, C., Talip, Z., Béhé, M. P., van der Meulen, N. P., Halin, C., Schibli, R., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01543-3 · Cited by 26
Rafael, T. S., Rotman, J., Brouwer, O. R., van der Poel, H. G., Mom, C. H., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041101 · Cited by 29
Wang, T., Denman, D., Bacot, S. M., & Feldman, G. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051181 · Cited by 28
Kubo, T., Hirohashi, Y., Tsukahara, T., Kanaseki, T., Murata, K., Morita, R., & Torigoe, T. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1976942 · Cited by 26
Jamison, B. L., Lawrance, M. F., Wang, C. J., DeBerg, H. A., Ziegler, L., Sansom, D. M., Gavin, M. A., Walker, L. S. K., & Campbell, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114938 · Cited by 29
Flies, A. S., Darby, J. M., Lennard, P. R., Murphy, P. R., Ong, C. E. B., Pinfold, T. L., Luca, A. D., Lyons, A. B., Woods, G. M., & Patchett, A. L. (2020) · Science Advances · doi:10.1126/sciadv.aba5031 · Cited by 24
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
Bocanegra, A., Blanco, E., Fernández-Hinojal, G., Arasanz, H., Chocarro, L., Zuazo, M., Morente, P., Vera, R., Escors, D., & Kochan, G. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165918 · Cited by 25
Désert, R., Giannone, F., Saviano, A., Hoshida, Y., Heikenwälder, M. F., Nahon, P., & Baumert, T. F. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00018-y · Cited by 26
Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes
Afroj, T., Mitsuhashi, A., Ogino, H., Saijo, A., Otsuka, K., Yoneda, H., Tobiume, M., Nguyen, N. T., Goto, H., Koyama, K., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000909 · Cited by 23
Therapeutic potential of cis-targeting bispecific antibodies
Oslund, R., Holland, P. M., Lesley, S. A., & Fadeyi, O. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.07.004 · Cited by 23
Yasumizu, Y., Kinoshita, M., Zhang, M. J., Motooka, D., Suzuki, K., Nojima, S., Koizumi, N., Okuzaki, D., Funaki, S., Shintani, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114677 · Cited by 33
Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
Re, V. D., Caggiari, L., Repetto, O., Mussolin, L., & Mascarin, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101596 · Cited by 25
Polyethyleneimine‐CpG Nanocomplex as an In Situ Vaccine for Boosting Anticancer Immunity in Melanoma
Xu, Y., Ma, S., Si, X., Zhao, J., Yu, H., Ma, L., Song, W., & Tang, Z. (2020) · Macromolecular Bioscience · doi:10.1002/mabi.202000207 · Cited by 23
Chen, R., Yuan, D., & Ma, J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0256 · Cited by 25
Estrada‐Capetillo, L., Aragoneses‐Fenoll, L., Domínguez‐Soto, Á., Fuentelsaz‐Romero, S., Nieto, C., Simón‐Fuentes, M., Alonso, B., Portolés, P., Corbí, A. L., Rojo, J. M., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202048806 · Cited by 22
Srivastava, P., Rütter, M., Antoniraj, G. M., Ventura, Y., & David, A. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c12821 · Cited by 24
Wang, X., Lu, L., Hong, X., Wu, L., Yang, C., Wang, Y., Li, W., Yang, Y., Cao, D., Di, W. J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113712 · Cited by 26
Hua, S., Gu, X., Jin, H., Zhang, X., Liu, Q., & Yang, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117080 · Cited by 24
Programmed Death Ligand 1-Expressing Classical Dendritic Cells Mitigate -Induced Gastritis
Go, D., Lee, S. H., Lee, S.-H., Woo, S., Kim, K., Kim, K., Park, K. S., Park, J., Ha, S., Kim, W. H., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.04.007 · Cited by 23
Sagrero‐Fabela, N., Chávez-Mireles, R., Salazar‐Camarena, D. C., & Palafox‐Sánchez, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147726 · Cited by 22
Palomba, M. L., Till, B. G., Park, S. I., Morschhauser, F., Cartron, G., Marks, R., Shivhare, M., Hong, W., Raval, A., Chang, A. C., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.12.010 · Cited by 25
Costimulation blockade and Tregs in solid organ transplantation
Muckenhuber, M., Wekerle, T., & Schwarz, C. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.969633 · Cited by 23
Kang-Pettinger, T., Walker, K., Brown, R., Cowan, R. H., Wright, H., Baravalle, R., Waters, L. C., Muskett, F. W., Bowler, M. W., Sawmynaden, K., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102769 · Cited by 22
Cancer resistance to immunotherapy: What is the role of cancer stem cells?
Gupta, G., Merhej, G., Saravanan, S., & Chen, H. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.19 · Cited by 24
TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways
Chan, W., Cao, Y. M., Zhao, X., Schrom, E. C., Jia, D., Song, J., Sibener, L. V., Dong, S., Fernandes, R. A., Bradfield, C. J., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20231242 · Cited by 23
Dendritic Cells (DCs) as “Fire Accelerants” of Hantaviral Pathogenesis
Schönrich, G., & Raftery, M. J. (2019) · Viruses · doi:10.3390/v11090849 · Cited by 21
Ding, L., Dong, H., Zhou, T. R., Wang, Y. H., Yan, T., Li, J. C., Wang, Z. Y., Liang, C., & Liang, C. (2021) · Cancer Medicine · doi:10.1002/cam4.4190 · Cited by 25
Mitsuhashi, A., Koyama, K., Ogino, H., Afroj, T., Nguyen, N. T., Yoneda, H., Otsuka, K., Sugimoto, M., Kondoh, O., Nokihara, H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112162 · Cited by 22
Feng, Y., Deyanat‐Yazdi, G., Newburn, K., Potter, S. C., Wortinger, M. A., Ramirez, M., Truhlar, S. M. E., & Yachi, P. P. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103339 · Cited by 20
Wang, B., Chen, C., Liu, X., Zhou, S. Y., Xu, T., & Wu, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111005 · Cited by 25
Gao, F., You, W., Zhang, L., Shen, A.-Z., Chen, G., Zhang, Z., Nie, X., Xia, L., Huang, W., Wang, L., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14394 · Cited by 21
Iwai, T., Sugimoto, M., Patil, N. S., Bower, D., Suzuki, M., Kato, C., Yorozu, K., Kurasawa, M., Shames, D. S., & Kondoh, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-93113-y · Cited by 20
A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets
Cai, Z., Ang, X., Xu, Z., Li, S., Zhang, J., Pei, C.-S., & Zhou, F. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-561 · Cited by 20
Okamura, H., Okazaki, I., Shimizu, K., Maruhashi, T., Sugiura, D., Mizuno, R., & Okazaki, T. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.06.007 · Cited by 20
Self-citationPD-1-stimulated T cell subsets are transcriptionally and functionally distinct
Lerrer, S., Tocheva, A. S., Bukhari, S., Adam, K., & Mor, A. (2021) · iScience · doi:10.1016/j.isci.2021.103020 · Cited by 19
Masullo, L. A., Kowalewski, R., Honsa, M., Heinze, L., Xu, S., Steen, P. R., Grabmayr, H., Pachmayr, I., Reinhardt, S. C. M., Perovic, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59500-z · Cited by 21
Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy
Prakash, A., Gates, T. J., Zhao, X., Wangmo, D., & Subramanian, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108332 · Cited by 23
Hu, C., Huang, C., Wang, J., Hong, Y. M., Fan, D., Chen, Y., Lin, A., Xiang, L., & Shao, J.-Z. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300217 · Cited by 19
Zhikun, G., Yu, J., Chen, Z., Chen, S., & Wang, L. (2024) · Biomedicines · doi:10.3390/biomedicines12040764 · Cited by 20
Research progress of CD80 in the development of immunotherapy drugs
Li, L., Yang, L., & Jiang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1496992 · Cited by 23
Abu‐Shah, E., Demetriou, P., Balint, S., Mayya, V., Kutuzov, M. A., Dushek, O., & Dustin, M. L. (2019) · eLife · doi:10.7554/elife.48221 · Cited by 20
PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment
Le, C. T., Khuat, L. T., Caryotakis, S. E., Wang, M., Dunai, C., Nguyen, A. V., Vick, L. V., Stoffel, K. M., Blazar, B. R., Monjazeb, A. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590568 · Cited by 21
Fas/FasL Signaling Regulates CD8 Expression During Exposure to Self-Antigens
Flores-Mendoza, G., Rodríguez‐Rodríguez, N., Rubio, R. M., Madera-Salcedo, I. K., Rosetti, F., & Crispín, J. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635862 · Cited by 19
Acquired Resistance to Immune Checkpoint Blockade Therapies
Zhao, X., Wangmo, D., Robertson, M. J., & Subramanian, S. (2020) · Cancers · doi:10.3390/cancers12051161 · Cited by 21
Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy
Awadasseid, A., Zhou, Y., Zhang, K., Tian, K., Wu, Y., & Zhang, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114057 · Cited by 19
Exosomes as a Therapeutic Strategy in Cancer: Potential Roles as Drug Carriers and Immune Modulators
Abedi, A., Moghaddam, M. M., Kachuei, R., & Fooladi, A. A. I. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189238 · Cited by 22
Lung, J., Hung, M., Lin, Y., Hung, C., Chen, C., Lee, K., & Tsai, Y. (2020) · Molecules · doi:10.3390/molecules25225293 · Cited by 18
Rodríguez-Barbosa, J.-I., Azuma, M., Zelinskyy, G., Pérez‐Simón, J. A., & del Rio, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02520-z · Cited by 18
Kantheti, U., Forward, T. S., Lucas, E. D., Schafer, J. B., Tamburini, P. J., Burchill, M. A., & Tamburini, B. A. J. (2025) · Science Advances · doi:10.1126/sciadv.adt3044 · Cited by 19
Wang, J., Cheng, F. H. C., Tedrow, J., Chang, W., Zhang, C., & Mitra, A. K. (2020) · Cancers · doi:10.3390/cancers12113184 · Cited by 18
T-cell-intrinsic and -extrinsic regulation of PD-1 function
Sugiura, D., Shimizu, K., Maruhashi, T., Okazaki, I., & Okazaki, T. (2021) · International Immunology · doi:10.1093/intimm/dxab077 · Cited by 17
Self-citationFeng, H., Zhao, Y., Yan, W., Wei, X., Lin, J.-P., Jiang, P., Wang, C., & Li, B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.843749 · Cited by 20
Inhibitory immune checkpoints in cancer immunotherapy
Tang, Z.-H., & Veillette, A. (2025) · Science Immunology · doi:10.1126/sciimmunol.adv6870 · Cited by 18
Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype
Desimpel, P.-H., Petit, P.-F., den Eynde, B. J. V., & Zhu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708873 · Cited by 23
The Role of Programmed Death-1 in Type 1 Diabetes
Tucker, C., Dwyer, A. J., Fife, B. T., & Martinov, T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01384-6 · Cited by 17
Cis Interactions of Membrane Receptors and Ligands
Hui, E. (2023) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-120420-103941 · Cited by 18
Jeon, S. H., You, G., Park, J., Chung, Y., Park, K., Kim, H., Jeon, J., Kim, Y., Son, W., Jeong, D. S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2864 · Cited by 17
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
Li, L., Pu, H., Zhang, X., Guo, X., Li, G., & Zhang, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104683 · Cited by 17
Mélique, S., Yang, C., & Lesourne, R. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.03.008 · Cited by 17
Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
Świderska, J., Kozłowski, M., Kwiatkowski, S., & Cymbaluk‐Płoska, A. (2021) · Cancers · doi:10.3390/cancers13236063 · Cited by 17
Zhang, B., Tan, H., Kuang, J., Zhou, B., Liang, S., Pang, X. Y., Ouyang, Y., Zhang, Z., Long, Y., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02487-4 · Cited by 17
Kwiecień, I., Rutkowska, E., Raniszewska, A., Sokołowski, R., Bednarek, J., Jahnz‐Różyk, K., Rzepecki, P., & Domagala-Kulawik, J. J. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03178-5 · Cited by 15
Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80
Liu, J.-Y., Yu, Z., Fu, Q.-Y., Zhang, L., Li, J., Wu, M., Liu, B., & Chen, G. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02369-w · Cited by 17
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
Li, X., Liu, Y., Gui, J., Gan, L., & Xue, J. (2024) · Advanced Science · doi:10.1002/advs.202400702 · Cited by 22
Metadata
- Authors
- Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T.
- Affiliations
- Institute of Advanced Medical Sciences, Tokushima University (JP)
- Corresponding author
- Sugiura, Daisuke
- Maruhashi, Takumi
- Okazaki, Il-mi
- Shimizu, Kenji
- Maeda, Takeo K.
- Okazaki, Taku
- ORCID
- Venue
- Science
- Published
- 2019-05-10
- Volume
- 364
- Issue
- 6440
- Pages
- 558-566
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2936616584
- Cited by
- 386
- References
- 40
- Citations by year
- 2026: 44 · 2025: 40 · 2024: 61 · 2023: 49 · 2022: 52 · 2021: 63 · 2020: 53 · 2019: 23
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP18am0301007)
- Japan Society for the Promotion of Science (JP18H05417)
- Core Research for Evolutional Science and Technology, Japan Science and Technology Agency
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, CD80, T cell activation, T cell suppression, costimulation, dendritic cells, anti-PD-1 therapy, PD-L1 blockade, cancer immunotherapy, immune checkpoint regulation
- MeSH terms
- Animals, Dendritic Cells, Humans, Immunotherapy, Lymphocyte Activation, Mice, Mutant Strains, Neoplasms, Protein Binding, T-Lymphocytes, Autoimmunity, CD28 Antigens, B7-1 Antigen, Mice, Gene Knock-In Techniques, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.